Re-examining the Immunological Origins of Kidney Stone Formation

Traditionally, kidney stones have been considered a condition where calcium and oxalate accumulate in the urinary tract, physically crystallizing. However, researchers at the University of Alabama at Birmingham (UAB) conducted a clinical trial based on the hypothesis that changes at the cellular level of the innate immune system are deeply involved in this process. The study aimed to determine whether changes in dietary oxalate intake could stimulate monocytes, an immune cell, to promote inflammation within the kidneys and accelerate stone formation. This expands kidney stone research beyond purely physical factors, into the realm of pathophysiological immune responses, which is significant as it suggests new therapeutic approaches.

Precise Biological Data Collection Through Contrasting Diets

This study was conducted as a randomized crossover trial, where 14 healthy subjects consumed a low-oxalate diet and a high-oxalate diet for four days each. Over a 24-hour period, urine was collected to analyze urinary oxalate excretion and crystalluria levels, and cellular energy status of monocytes in the blood was precisely measured. When consuming a low-oxalate diet, urinary oxalate excretion averaged 8.59 mg/day (SE 1.00), but when consuming a high-oxalate diet, it increased to 13.97 mg/day (SE 2.38), representing an approximately 62.6% increase. In terms of crystalluria, the low-oxalate diet group showed an average of 816 million particles/ml (SE 90 million), while the high-oxalate diet group showed an average of 850 million particles/ml (SE 96.2 million), quantitatively demonstrating a significant change in crystal formation according to dietary patterns.

Linking Mitochondrial Dysfunction in Immune Cells to Kidney Stones

In particular, a key finding of this clinical trial is the completion of both urinary crystal formation analysis and cellular oxygen consumption rate changes and transcriptomics analysis of monocytes. The study revealed that when high concentrations of oxalate are absorbed, the energy of mitochondria in monocytes, which are responsible for innate immunity, is damaged, leading to excessive production of reactive oxygen species (ROS) and inducing abnormal activation of innate immune cells. When immune cells lose their normal metabolic activity and turn into an inflammatory state, they cause damage to kidney cells and create an environment where stone crystals are easily deposited. This goes beyond simple chemical reactions in the urine and suggests the scientific validity of preventing kidney stones through immune regulation.

Paradigm Shift from Prevention to Precision Immunotherapy

These results open the door to the development of new therapeutic agents that target the immune system, moving beyond existing supportive treatments that simply increase fluid intake or take citrate. Currently, there are treatments for primary hyperoxaluria, a rare disease, such as Oxlumo (lumasiran) from Alnylam and Rivfloza (nedosiran) from Novo Nordisk, but there are no immune therapies targeting general kidney stone patients. In the future, the commercialization potential of a pipeline for general kidney stone prevention using TLR4 signaling pathway inhibitors in monocytes or mitochondrial-targeted antioxidants is expected to be very promising.